Few differences were found for cardiovascular, kidney, and mortality outcomes between liraglutide, semaglutide, and dulaglutide for patients with type 2 diabetes.

"As of now, semaglutide is FDA-indicated for slowing chronic kidney disease progression, [but] our results suggest that ...

Rhode Island’s Medicaid program is contemplating an end to coverage for GLP-1 drugs prescribed for weight loss. The proposal ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.

Key Points Chesapeake sold 9,875 Eli Lilly and Company shares; estimated trade value of approximately $7.68 million, based on the average price for Q2 2025 Transaction represented 6.9% of fund AUM.